Development and validation of a LC-MS/MS method for determination of bivalirudin in human plasma: Application to a clinical pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 1, 2010, Pages 105-109

  Pan, Guixiang ^a   Wang, Xiaoming ^a   Huang, Yuhong ^a   Gao, Xiumei ^a   Wang, Yuefei ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Anticoagulant; Bivalirudin; Peptide LC MS MS; Pharmacokinetics

Indexed keywords

HIRULOG; METHANOL; NAFARELIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG IDENTIFICATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; PRECIPITATION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; VOLUNTEER;

ADULT; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, LIQUID; FEMALE; HIRUDINS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 74249104371     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.12.002     Document Type: Article

References (9)

1. Moen M.D., Keating G.M., and Wellington K. Bivalirudin-a review of its use in patients undergoing percutaneous coronary intervention. Drugs 65 (2005) 1869-1891
2. Lepor N.E. Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors. Rev. Cardiovasc. Med. 8 (2007) S9-17
3. Robson R. The use of bivalirudin in patients with renal impairment. J. Invasive Cardiol. 12 Suppl. F (2000) 33-36
4. Koster A., Spiess B., Jurmann M., Dyke C.M., Smedira N.G., Aronson S., and Lincoff M.A. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial. Anesth. Analg. 103 (2006) 540-544
5. Koster A., Spiess B., Chew D.P., Krabatsch T., Tambeur L., DeAnda A., Hetzer R., Kuppe H., Smedira N.G., and Lincoff A.M. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am. J. Cardiol. 93 (2004) 356-359
6. Farthing D., Larus T., Fakhry I., Gehr T., Prats J., and Sica D. Liquid chromatography method for determination of bivalirudin in human plasma and urine using automated ortho-phthalaldehyde derivatization and fluorescence detection. J. Chromatogr. B 802 (2004) 355-359
7. Robson R., White H., Aylward P., and Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin. Pharmacol. Ther. 71 (2002) 433-439
8. Roepstorff P., and Fohlman J. Proposal for a common nomenclature for sequence ions in mass spectra of peptides. Biomed. Mass Spectrom. 11 (1984) 601
9. Johnson R.S., Martin S.A., Biemann K., Stults J.T., and Watson J.T. Novel fragmentation process of peptides by collision-induced decomposition in a tandem mass spectrometer: differentiation of leucine and isoleucine. Anal. Chem. 59 (1987) 2621-2625